Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,563.63
(
0.58%
)
US TECH 100
29,445.20
(
0.92%
)
Dow Jones
50,668.97
(
0.05%
)
Brent Oil
92.18
(
-0.28%
)
Bitcoin
73,555.76
(
-1.78%
)
News Focus
News Focus
Post# of 518903
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

frrol

Send PM Follow Ignore
Followers 96
Posts 12271
Boards Moderated 0
Alias Born 06/06/2014

frrol

Re: Doc328 post# 333343

Wednesday, 10/20/2021 2:32:33 PM

Wednesday, October 20, 2021 2:32:33 PM

Post# of 518903
Yes. And the company's thesis is that our drugs, which are S1 agonist like PRE-084, are safer, and that they're worth testing in humans with real disease to see if the MOA is truly therapeutic.

And so the dissembling of formerly valid proclamations on hidden S1 antagonists by a competent researcher. I suspect the importance of clinical trials vs "mouse(murine)" models are a little clearer now.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News